Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 66

1.

Systematic review and meta-analysis of randomised controlled clinical trial evidence refutes relationship between pharmacotherapy with angiotensin-receptor blockers and an increased risk of cancer.

Datzmann T, Fuchs S, Andree D, Hohenstein B, Schmitt J, Schindler C.

Eur J Intern Med. 2019 Jun;64:1-9. doi: 10.1016/j.ejim.2019.04.019. Epub 2019 May 3. Review.

PMID:
31060961
2.

[Membranoproliferative glomerulonephritis and C3 glomerulopathy].

Hohenstein B, Amann K, Menne J.

Internist (Berl). 2019 May;60(5):458-467. doi: 10.1007/s00108-019-0572-0. Review. German.

PMID:
30859280
3.

Lipoprotein apheresis is an optimal therapeutic option to reduce increased Lp(a) levels.

Schettler VJJ, Neumann CL, Peter C, Zimmermann T, Julius U, Hohenstein B, Roeseler E, Heigl F, Grützmacher P, Blume H, Klingel R, Vogt A; Scientific Board of GLAR for the German Apheresis Working Group.

Clin Res Cardiol Suppl. 2019 Apr;14(Suppl 1):33-38. doi: 10.1007/s11789-019-00094-4.

PMID:
30838552
4.

Treatment-related and health-related quality of life in lipoprotein apheresis patients.

De Gucht V, Cromm K, Vogt A, Julius U, Hohenstein B, Spitthöver RM, Ramlow W, Schettler VJJ, Maes S.

J Clin Lipidol. 2018 Sep - Oct;12(5):1225-1233. doi: 10.1016/j.jacl.2018.05.008. Epub 2018 May 26.

PMID:
29921556
5.

Progenitor Renin Lineage Cells are not involved in the regeneration of glomerular endothelial cells during experimental renal thrombotic microangiopathy.

Ruhnke L, Sradnick J, Al-Mekhlafi M, Gerlach M, Gembardt F, Hohenstein B, Todorov VT, Hugo C.

PLoS One. 2018 May 17;13(5):e0196752. doi: 10.1371/journal.pone.0196752. eCollection 2018.

6.

ADMA reduction does not protect mice with streptozotocin-induced diabetes mellitus from development of diabetic nephropathy.

Rodionov RN, Heinrich A, Brilloff S, Jarzebska N, Martens-Lobenhoffer J, Bode-Böger SM, Todorov VT, Hugo CPM, Weiss N, Hohenstein B.

Atheroscler Suppl. 2017 Nov;30:319-325. doi: 10.1016/j.atherosclerosissup.2017.05.031. Epub 2017 Jun 1.

PMID:
29096857
7.

How effectively will PCSK9 inhibitors allow retrieval of freedom from apheresis in cardiovascular high risk patients? - Estimates form a large single center.

Hohenstein B, Tselmin S, Bornstein SR, Julius U.

Atheroscler Suppl. 2017 Nov;30:28-32. doi: 10.1016/j.atherosclerosissup.2017.05.012. Epub 2017 May 31.

PMID:
29096851
8.

Low rate of infectious complications following immunoadsorption therapy without regular substitution of intravenous immunoglobulins.

Tselmin S, Julius U, Bornstein SR, Hohenstein B.

Atheroscler Suppl. 2017 Nov;30:278-282. doi: 10.1016/j.atherosclerosissup.2017.05.010. Epub 2017 Jun 1.

PMID:
29096850
9.

Successful and well-tolerated bi-weekly immunoadsorption regimen in pemphigus vulgaris.

Dietze J, Hohenstein B, Tselmin S, Julius U, Bornstein SR, Beissert S, Günther C.

Atheroscler Suppl. 2017 Nov;30:271-277. doi: 10.1016/j.atherosclerosissup.2017.05.044. Epub 2017 Jun 3.

PMID:
29096849
10.

Comparing the efficacy of three techniques to reduce isoagglutinin titers in AB0 incompatible kidney transplant recipients.

Parmentier SP, Rosenkranz E, Schirutschke H, Opgenoorth M, Quick C, Hoelig K, Rosner A, Hohenstein B, Hugo C, Passauer J.

Atheroscler Suppl. 2017 Nov;30:253-256. doi: 10.1016/j.atherosclerosissup.2017.05.017. Epub 2017 Jun 1.

PMID:
29096846
11.

Most significant reduction of cardiovascular events in patients undergoing lipoproteinapheresis due to raised Lp(a) levels - A multicenter observational study.

Schatz U, Tselmin S, Müller G, Julius U, Hohenstein B, Fischer S, Bornstein SR.

Atheroscler Suppl. 2017 Nov;30:246-252. doi: 10.1016/j.atherosclerosissup.2017.05.047. Epub 2017 Jun 3.

PMID:
29096845
12.

Dysregulation of the CD4+ T cells lineage differentiation in dyslipidemic patients and impact of lipoprotein-apheresis treatment: A case study.

Papin J, Brennand A, Arbore G, Hohenstein B, Kamvissi V, Kemper C, Bornstein SR.

Atheroscler Suppl. 2017 Nov;30:238-245. doi: 10.1016/j.atherosclerosissup.2017.05.046. Epub 2017 Jun 3.

PMID:
29096844
13.

H.E.L.P apheresis exerts long term effects on the capacity of circulating proangiogenic cells.

Sradnick J, Tselmin S, Wagner A, Julius U, Todorov V, Hugo C, Hohenstein B.

Atheroscler Suppl. 2017 Nov;30:232-237. doi: 10.1016/j.atherosclerosissup.2017.05.045. Epub 2017 Jun 2.

PMID:
29096843
14.

Kinetics of Lipoprotein(a) in patients undergoing weekly lipoprotein apheresis for Lp(a) hyperlipoproteinemia.

Tselmin S, Müller G, Schatz U, Julius U, Bornstein SR, Hohenstein B.

Atheroscler Suppl. 2017 Nov;30:209-216. doi: 10.1016/j.atherosclerosissup.2017.05.033.

PMID:
29096840
15.

Rationale and design of MultiSELECt: A European Multicenter Study on the Effect of Lipoprotein(a) Elimination by lipoprotein apheresis on Cardiovascular outcomes.

Hohenstein B, Julius U, Lansberg P, Jaeger B, Mellwig KP, Weiss N, Graehlert X, Roeder I, Ramlow W.

Atheroscler Suppl. 2017 Nov;30:180-186. doi: 10.1016/j.atherosclerosissup.2017.05.009. Epub 2017 Jun 1.

PMID:
29096835
16.

Long-term follow-up of circulating oxidative stress markers in patients undergoing lipoprotein apheresis by Direct Adsorption of Lipids (DALI).

Kopprasch S, Bornstein SR, Bergmann S, Graessler J, Hohenstein B, Julius U.

Atheroscler Suppl. 2017 Nov;30:115-121. doi: 10.1016/j.atherosclerosissup.2017.05.029. Epub 2017 Jun 1.

PMID:
29096826
17.

Lipoprotein apheresis influences monocyte subpopulations.

Jellinghaus S, Reich C, Schatz U, Tselmin S, Ibrahim K, Pfluecke C, Schauer A, Bornstein SR, Hohenstein B, Strasser RH, Julius U, Poitz DM.

Atheroscler Suppl. 2017 Nov;30:108-114. doi: 10.1016/j.atherosclerosissup.2017.05.027. Epub 2017 Jun 1.

PMID:
29096825
18.

Interference with Gsα-Coupled Receptor Signaling in Renin-Producing Cells Leads to Renal Endothelial Damage.

Lachmann P, Hickmann L, Steglich A, Al-Mekhlafi M, Gerlach M, Jetschin N, Jahn S, Hamann B, Wnuk M, Madsen K, Djonov V, Chen M, Weinstein LS, Hohenstein B, Hugo CPM, Todorov VT.

J Am Soc Nephrol. 2017 Dec;28(12):3479-3489. doi: 10.1681/ASN.2017020173. Epub 2017 Aug 3.

19.

Persistent and inducible neogenesis repopulates progenitor renin lineage cells in the kidney.

Hickmann L, Steglich A, Gerlach M, Al-Mekhlafi M, Sradnick J, Lachmann P, Sequeira-Lopez MLS, Gomez RA, Hohenstein B, Hugo C, Todorov VT.

Kidney Int. 2017 Dec;92(6):1419-1432. doi: 10.1016/j.kint.2017.04.014. Epub 2017 Jul 6.

20.

The PPAR-gamma-binding sequence Pal3 is necessary for basal but dispensable for high-fat diet regulated human renin expression in the kidney.

Lachmann P, Selbmann J, Hickmann L, Hohenstein B, Hugo C, Todorov VT.

Pflugers Arch. 2017 Oct;469(10):1349-1357. doi: 10.1007/s00424-017-1994-y. Epub 2017 May 22.

PMID:
28534088
21.

Lipoprotein(a) in nephrological patients.

Hohenstein B.

Clin Res Cardiol Suppl. 2017 Mar;12(Suppl 1):27-30. doi: 10.1007/s11789-017-0086-z. Review.

22.

Peritubular capillaries: an important piece of the puzzle.

Hohenstein B, Hugo C.

Kidney Int. 2017 Jan;91(1):9-11. doi: 10.1016/j.kint.2016.08.033.

PMID:
28003093
23.

Monitoring of complement activation biomarkers and eculizumab in complement-mediated renal disorders.

Wehling C, Amon O, Bommer M, Hoppe B, Kentouche K, Schalk G, Weimer R, Wiesener M, Hohenstein B, Tönshoff B, Büscher R, Fehrenbach H, Gök ÖN, Kirschfink M.

Clin Exp Immunol. 2017 Feb;187(2):304-315. doi: 10.1111/cei.12890. Epub 2016 Nov 25.

24.

Alirocumab in patients with heterozygous familial hypercholesterolaemia undergoing lipoprotein apheresis: the ODYSSEY ESCAPE trial.

Moriarty PM, Parhofer KG, Babirak SP, Cornier MA, Duell PB, Hohenstein B, Leebmann J, Ramlow W, Schettler V, Simha V, Steinhagen-Thiessen E, Thompson PD, Vogt A, von Stritzky B, Du Y, Manvelian G.

Eur Heart J. 2016 Dec 21;37(48):3588-3595. doi: 10.1093/eurheartj/ehw388. Epub 2016 Aug 29.

25.

Alirocumab in patients with heterozygous familial hypercholesterolemia undergoing lipoprotein apheresis: Rationale and design of the ODYSSEY ESCAPE trial.

Moriarty PM, Parhofer KG, Babirak SP, deGoma E, Duell PB, Hohenstein B, Ramlow W, Simha V, Steinhagen-Thiessen E, Thompson PD, Vogt A, von Stritzky B, Du Y, Manvelian G.

J Clin Lipidol. 2016 May-Jun;10(3):627-34. doi: 10.1016/j.jacl.2016.02.003. Epub 2016 Feb 18.

PMID:
27206951
26.

Acetylation of asymmetric and symmetric dimethylarginine: an undercharacterized pathway of metabolism of endogenous methylarginines.

Rodionov RN, Martens-Lobenhoffer J, Brilloff S, Burdin DV, Jarzebska N, Demyanov AV, Hohenstein B, Weiss N, Bode-Böger SM.

Nephrol Dial Transplant. 2016 Jan;31(1):57-63. doi: 10.1093/ndt/gfv390. Epub 2015 Nov 25.

PMID:
26610597
27.

Extrarenal Progenitor Cells Do Not Contribute to Renal Endothelial Repair.

Sradnick J, Rong S, Luedemann A, Parmentier SP, Bartaun C, Todorov VT, Gueler F, Hugo CP, Hohenstein B.

J Am Soc Nephrol. 2016 Jun;27(6):1714-26. doi: 10.1681/ASN.2015030321. Epub 2015 Oct 9.

28.

Effects of Lipoprotein apheresis on the Lipoprotein(a) levels in the long run.

Groß E, Hohenstein B, Julius U.

Atheroscler Suppl. 2015 May;18:226-32. doi: 10.1016/j.atherosclerosissup.2015.02.033.

PMID:
25936330
29.

Actual situation of lipoprotein apheresis in Saxony in 2013.

Emmrich U, Hohenstein B, Julius U.

Atheroscler Suppl. 2015 May;18:215-25. doi: 10.1016/j.atherosclerosissup.2015.02.034.

PMID:
25936329
30.

Increasing plasma lysophosphatidylcholine levels in patients with regular dextran sulfate lipoprotein apheresis.

Graessler J, Schuhmann K, Shevchenko A, Kopprasch S, Ban R, Bergmann S, Bornstein SR, Hohenstein B, Julius U.

Atheroscler Suppl. 2015 May;18:170-5. doi: 10.1016/j.atherosclerosissup.2015.02.026.

PMID:
25936322
31.

Immunoadsorption with regenerating systems in neurological disorders --A single center experience.

Hohenstein B, Passauer J, Ziemssen T, Julius U.

Atheroscler Suppl. 2015 May;18:119-23. doi: 10.1016/j.atherosclerosissup.2015.02.022.

PMID:
25936315
32.

Effects of different lipoprotein apheresis methods on serum protein levels.

Julius U, Siegert G, Kostka H, Schatz U, Hohenstein B.

Atheroscler Suppl. 2015 May;18:95-102. doi: 10.1016/j.atherosclerosissup.2015.02.018.

PMID:
25936311
33.

Treatment of antibody-mediated rejection including immunoadsorption during first year after renal transplantation--Clinical results and regulation of endothelial progenitor cells.

Opgenoorth M, Wagner A, Passauer J, Hohenstein B, Hugo C.

Atheroscler Suppl. 2015 May;18:67-73. doi: 10.1016/j.atherosclerosissup.2015.02.014.

PMID:
25936307
34.

Adverse events of lipoprotein apheresis and immunoadsorption at the Apheresis Center at the University Hospital Dresden.

Dittrich-Riediger J, Schatz U, Hohenstein B, Julius U.

Atheroscler Suppl. 2015 May;18:45-52. doi: 10.1016/j.atherosclerosissup.2015.02.007.

PMID:
25936304
35.

Platelets are relevant mediators of renal injury induced by primary endothelial lesions.

Schwarzenberger C, Sradnick J, Lerea KM, Goligorsky MS, Nieswandt B, Hugo CP, Hohenstein B.

Am J Physiol Renal Physiol. 2015 Jun 1;308(11):F1238-46. doi: 10.1152/ajprenal.00535.2014. Epub 2015 Apr 1.

36.

Neutrophil Extracellular Trap-Related Extracellular Histones Cause Vascular Necrosis in Severe GN.

Kumar SV, Kulkarni OP, Mulay SR, Darisipudi MN, Romoli S, Thomasova D, Scherbaum CR, Hohenstein B, Hugo C, Müller S, Liapis H, Anders HJ.

J Am Soc Nephrol. 2015 Oct;26(10):2399-413. doi: 10.1681/ASN.2014070673. Epub 2015 Feb 2.

37.

A new apparatus for standardized rat kidney biopsy.

Schirutschke H, Gladrow L, Norkus C, Parmentier SP, Hohenstein B, Hugo CP.

PLoS One. 2014 Dec 15;9(12):e115368. doi: 10.1371/journal.pone.0115368. eCollection 2014.

38.

Role of alanine:glyoxylate aminotransferase 2 in metabolism of asymmetric dimethylarginine in the settings of asymmetric dimethylarginine overload and bilateral nephrectomy.

Rodionov RN, Martens-Lobenhoffer J, Brilloff S, Hohenstein B, Jarzebska N, Jabs N, Kittel A, Maas R, Weiss N, Bode-Böger SM.

Nephrol Dial Transplant. 2014 Nov;29(11):2035-42. doi: 10.1093/ndt/gfu236. Epub 2014 Jul 6.

PMID:
25002409
39.

The SGLT2 inhibitor empagliflozin ameliorates early features of diabetic nephropathy in BTBR ob/ob type 2 diabetic mice with and without hypertension.

Gembardt F, Bartaun C, Jarzebska N, Mayoux E, Todorov VT, Hohenstein B, Hugo C.

Am J Physiol Renal Physiol. 2014 Aug 1;307(3):F317-25. doi: 10.1152/ajprenal.00145.2014. Epub 2014 Jun 18.

40.

Renin lineage cells repopulate the glomerular mesangium after injury.

Starke C, Betz H, Hickmann L, Lachmann P, Neubauer B, Kopp JB, Sequeira-Lopez ML, Gomez RA, Hohenstein B, Todorov VT, Hugo CP.

J Am Soc Nephrol. 2015 Jan;26(1):48-54. doi: 10.1681/ASN.2014030265. Epub 2014 Jun 5.

41.

Immunoadsorption for connective tissue disease.

Hohenstein B, Bornstein SR, Aringer M.

Atheroscler Suppl. 2013 Jan;14(1):185-9. doi: 10.1016/j.atherosclerosissup.2012.10.034. Review.

PMID:
23357163
42.

In vivo evidence that Agxt2 can regulate plasma levels of dimethylarginines in mice.

Kittel A, Maas R, König J, Mieth M, Weiss N, Jarzebska N, Hohenstein B, Martens-Lobenhoffer J, Bode-Böger SM, Rodionov RN.

Biochem Biophys Res Commun. 2013 Jan 4;430(1):84-9. doi: 10.1016/j.bbrc.2012.11.008. Epub 2012 Nov 12.

PMID:
23154179
43.

[Diabetes and the kidneys].

Hohenstein B, Hugo C.

Dtsch Med Wochenschr. 2012 Oct;137(40):1998-2001. Epub 2012 Sep 28. German. No abstract available.

PMID:
23023609
44.

Platelets are not critical effector cells for the time course of murine passive crescentic glomerulonephritis.

Hohenstein B, Daniel C, Johnson RJ, Amann KU, Hugo CP.

Platelets. 2013;24(4):267-74. doi: 10.3109/09537104.2012.684731. Epub 2012 Jul 10.

PMID:
22779773
45.

Histones from dying renal cells aggravate kidney injury via TLR2 and TLR4.

Allam R, Scherbaum CR, Darisipudi MN, Mulay SR, Hägele H, Lichtnekert J, Hagemann JH, Rupanagudi KV, Ryu M, Schwarzenberger C, Hohenstein B, Hugo C, Uhl B, Reichel CA, Krombach F, Monestier M, Liapis H, Moreth K, Schaefer L, Anders HJ.

J Am Soc Nephrol. 2012 Aug;23(8):1375-88. doi: 10.1681/ASN.2011111077. Epub 2012 Jun 7.

46.

Chicken ovalbumin upstream promoter transcription factor II regulates renin gene expression.

Mayer S, Roeser M, Lachmann P, Ishii S, Suh JM, Harlander S, Desch M, Brunssen C, Morawietz H, Tsai SY, Tsai MJ, Hohenstein B, Hugo C, Todorov VT.

J Biol Chem. 2012 Jul 13;287(29):24483-91. doi: 10.1074/jbc.M111.329474. Epub 2012 May 29.

47.

Transgelin is a marker of repopulating mesangial cells after injury and promotes their proliferation and migration.

Daniel C, Lüdke A, Wagner A, Todorov VT, Hohenstein B, Hugo C.

Lab Invest. 2012 Jun;92(6):812-26. doi: 10.1038/labinvest.2012.63. Epub 2012 Apr 2.

48.

PDGF-C mediates glomerular capillary repair.

Boor P, van Roeyen CR, Kunter U, Villa L, Bücher E, Hohenstein B, Hugo CP, Eriksson U, Satchell SC, Mathieson PW, Eitner F, Floege J, Ostendorf T.

Am J Pathol. 2010 Jul;177(1):58-69. doi: 10.2353/ajpath.2010.091008. Epub 2010 May 20.

49.

Autocrine VEGF-VEGF-R loop on podocytes during glomerulonephritis in humans.

Hohenstein B, Colin M, Foellmer C, Amann KU, Brekken RA, Daniel C, Hugo CP.

Nephrol Dial Transplant. 2010 Oct;25(10):3170-80. doi: 10.1093/ndt/gfq200. Epub 2010 Apr 15.

PMID:
20395257
50.

Enhanced progenitor cell recruitment and endothelial repair after selective endothelial injury of the mouse kidney.

Hohenstein B, Kuo MC, Addabbo F, Yasuda K, Ratliff B, Schwarzenberger C, Eckardt KU, Hugo CP, Goligorsky MS.

Am J Physiol Renal Physiol. 2010 Jun;298(6):F1504-14. doi: 10.1152/ajprenal.00025.2010. Epub 2010 Mar 17.

Supplemental Content

Loading ...
Support Center